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Abstract: Schistosomes, parasitic flatworms that cause
the tropical disease schistosomiasis, are still a threat. They
are responsible for 200 million infections worldwide and
an estimated 280,000 deaths annually in sub-Saharan
Africa alone. The adult parasites reside as pairs in the
mesenteric or perivesicular veins of their human host,
where they can survive for up to 30 years. The parasite is a
potential activator of blood coagulation according to
Virchow’s triad, because it is expected to alter blood flow
and endothelial function, leading to hypercoagulability. In
contrast, hepatosplenic schistosomiasis patients are in a
hypocoagulable and hyperfibrinolytic state, indicating
that schistosomes interfere with the haemostatic system
of their host. In this review, the interactions of schisto-
somes with primary haemostasis, secondary haemostasis,
fibrinolysis, and the vascular tone will be discussed to
provide insight into the reduction in coagulation ob-
served in schistosomiasis patients. Interference with the
haemostatic system by pathogens is a common mecha-
nism and has been described for other parasitic worms,
bacteria, and fungi as a mechanism to support survival
and spread or enhance virulence. Insight into the
mechanisms used by schistosomes to interfere with the
haemostatic system will provide important insight into
the maintenance of the parasitic life cycle within the host.
This knowledge may reveal new potential anti-schisto-
some drug and vaccine targets. In addition, some of the
survival mechanisms employed by schistosomes might be
used by other pathogens, and therefore, these mecha-
nisms that interfere with host haemostasis might be a
broad target for drug development against blood-
dwelling pathogens. Also, schistosome antithrombotic or
thrombolytic molecules could form potential new drugs
in the treatment of haemostatic disorders.
Introduction
The haemostatic system consists of procoagulant and anticoag-
ulant mechanisms that stop bleeding at sites of blood vessel injury
and play an important role in innate immunity [1–3]. Procoag-
ulant mechanisms of the haemostatic system can be further
divided into primary and secondary haemostasis. Primary
haemostasis involves the activation and aggregation of blood
platelets, whereas secondary haemostasis involves a cascade of
proteolytic reactions that lead to the formation of a stable fibrin
clot. Anticoagulant mechanisms of the haemostatic system include
inhibitors of primary and secondary haemostasis and the
fibrinolytic activity of plasmin that leads to degradation of formed
fibrin clots [2]. According to Virchow’s triad, three conditions can
contribute to the initiation of blood coagulation: normal blood
flow is disrupted or altered (stasis); the endothelium is damaged or
dysfunctional; and/or the coagulability of blood plasma is
increased (hypercoagulability) [4–6]. In order to maintain and
propagate themselves in blood vessels, many blood-dwelling
pathogens not only require adaptations to evade the actions of
the host immune system but also need to avoid blood coagulation
through interference with the haemostatic system of their host.
Schistosomes, blood-dwelling parasitic flatworms, are the cause of
the tropical disease schistosomiasis [7]. On average, adult
schistosomes reside in their host’s bloodstream for three to five
years, but their individual lifespan can be as long as 30 years [7].
Schistosomes can be expected to activate coagulation according to
Virchow’s triad by inducing stasis and alterations in endothelial
function [8,9]. The adult schistosome pair disturbs blood flow due
to the large size of the worm pair: 1 cm long with a diameter of
1 mm (Figure 1). Light microscopy images of adult worms inside
the mesenteric veins showed that the worm pair occupies the
major part of the lumen of the blood vessels in which they reside
[8,10]. This obstruction will induce turbulence in the vein and
increase shear stress along the vessel wall. Turbulence has been
described to contribute to the formation of thrombi [11].
Furthermore, endothelial cells can be activated by oscillatory
blood flow, which is characterized by forward–reverse flow cycles
and disrupted blood flow downstream of sites where the vessel
lumen is narrowed [12]. This leads to increased expression of
molecules involved in blood coagulation and modulation of the
vascular tone, such as tissue factor (TF), von Willebrand Factor
(VWF), tissue-type plasminogen activator (t-PA), nitric oxide (NO),
and prostacyclin (PGI2) [13–18]. Turbulence and changes in shear
stress, induced by the presence of the adult schistosome pair in the
blood vessel, could potentially activate platelets and blood
coagulation [4,11]. In addition, although there is no direct
evidence of endothelial damage caused by the presence of the
adult worm pair in the vein, several studies suggest that
schistosomes disturb endothelial cell function, and it has been
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suggested that the presence of the adult worm in the vein induces
endothelial damage [9,19–21]. In murine schistosomiasis, the
expression of endothelial NO synthase as well as the production of
NO are decreased, which indicates endothelial dysfunction
[9,19,21]. Furthermore, plasma soluble intercellular adhesion
molecule-1 is increased in hepatosplenic schistosomiasis patients,
which indicates endothelial activation and inflammation [22].
Extravasation of schistosome eggs may also contribute to
endothelial damage or dysfunction, since this disrupts the
polarization of the endothelium and causes mobilization and
migration of endothelial cells [8]. Therefore, it is likely that
parasite-induced alteration in endothelial function or endothelial
damage plays a role in activation of blood coagulation. Besides
alterations in blood flow and endothelial function, schistosomes
have many electronegative charges on their surfaces that could
potentially activate platelets and the coagulation cascade, leading
to hypercoagulation [23]. Thus, schistosomes have all the
characteristics to be potent activators of blood coagulation.
However, schistosomiasis patients do not have an increased risk
of thrombus formation [24]. In contrast, studies on blood
coagulation in hepatosplenic schistosomiasis patients (reviewed
by Tanabe [24]) showed that patients have prolonged coagulation
times [25]. In infected humans, major haemostatic abnormalities
are only observed in hepatosplenic schistosomiasis patients, but
murine studies observed changes in the activity of several
coagulation factors already during the early phase of schistosomi-
asis [26]. Hepatosplenic schistosomiasis patients have a reduced
activity or reduced levels of the coagulation factors II, VII, IX, X,
XI, XII, fibrinogen, high–molecular-weight kininogen (HMWK),
and prekallikrein, as well as the regulatory proteins antithrombin
and protein C [27,28]. Furthermore, the levels of thrombin-
antithrombin complexes, prothrombin fragment 1+2, plasma
fibrinopeptide A, D-dimers, and other fibrin degradation products
are increased in these patients [25,29]. The elevated levels of both
markers of coagulation activation (e.g., prothrombin fragment 1+2
and plasma fibrinopeptide A) as well as markers of fibrinolysis (e.g.,
fibrin degradation products) indicate a continuous activation of
both blood coagulation and fibrinolysis in hepatosplenic schisto-
somiasis patients. Therefore, the observed hypocoagulable and
hyperfibrinolytic state of these individuals is the result of both
increased consumption of coagulation factors and decreased
hepatic synthesis of these factors and cannot solely be attributed
to hepatic dysfunction [24,29]. Also, research showed that blood
platelets do not adhere to adult schistosomes or isolated outer
surface membranes (tegument) of adult worms [30]. It is thus clear
that schistosomes must have mechanisms that suppress the
haemostatic response of their host. In this review, the interactions
of schistosomes with primary haemostasis, secondary haemostasis,
fibrinolysis, and the vascular tone will be discussed in order to
provide insight into the reduction in blood coagulation that is
observed in schistosomiasis patients.
Identification of schistosome mechanisms that interfere with the
haemostatic system provides important insight into the mainte-
nance of the parasitic life cycle within its host. Insight into survival
mechanisms of the parasite could provide important clues for
novel anti-schistosome drugs or reveal vaccine targets. In addition,
other blood-dwelling pathogens face similar survival challenges
and may therefore employ similar survival strategies as schisto-
somes. These mechanisms that interfere with host haemostasis
may, therefore, form a broad target for drug development against
blood-dwelling pathogens. Also, potent antithrombotic drugs that
are currently used in the clinic have been isolated earlier from
pathogens, such as streptokinase from Streptococci [31]. Schistosome
antithrombotic or thrombolytic molecules could therefore form
potential novel drugs in the treatment of haemostatic disorders.
Interference with Primary Haemostasis by
Schistosomes
Primary haemostasis consists of the activation and aggregation
of blood platelets. Platelet activation can be triggered by
endothelial damage, which leads to exposure of the underlying
collagen, or by the presence of soluble activators, such as thrombin
or ADP. When the vessel wall is damaged, platelets will adhere to
collagen-bound vWF through glycoprotein Ib (GPIb) present on
their surface, followed by their activation and degranulation.
Under pathophysiological conditions VWF also binds to surfaces
of pathogens, such as Staphylococcus aureus, and triggers platelet
activation [32]. Activated platelets release factors, such as ADP
and thromboxane A2, which induce vasoconstriction, stimulate
secondary coagulation, and promote further platelet activation
and aggregation, resulting in the formation of a stable platelet plug
[2]. Several mechanisms have been described that could explain
the ability of schistosomes to prevent primary haemostasis
(Figure 2).
Ngaiza and Doenhoff observed a decreased platelet count, also
called thrombocytopenia, during schistosome infection in mice
[33]. This was suggested to contribute to the observed decrease in
platelet aggregation around the adult schistosome pair. In
schistosomiasis patients, a decreased platelet count was also
observed, but symptoms that are commonly observed in patients
with thrombocytopenia, e.g., gingival bleeding, are not present in
these patients, indicating that platelet aggregation is not fully
impaired [34]. Schistosomes must therefore have evolved addi-
tional mechanisms to prevent primary haemostasis.
Extracellular ADP induces platelet aggregation. ADP-mediated
platelet aggregation is normally controlled by ATP-diphosphohy-
drolase (ATPDase) proteins, such as CD39/ATPDase1, that are
present on endothelial cells [35,36]. These ATPDases hydrolyse
ATP to ADP and ADP to AMP and subsequently to adenosine.
This degradation of ADP and the subsequent formation of the
inhibitor adenosine leads to inhibition of ADP-mediated platelet
activation and aggregation [37,38]. The schistosome tegument
contains several enzymatic activities that could lead to the
degradation of extracellular ATP or ADP [39]. Alkaline
phosphatase activity is present in the tegument of Schistosoma
mansoni, and recombinant S. mansoni alkaline phosphatase (SmAP)
has been characterized [40,41]. Alkaline phosphatase enzymes are
present in many organisms and hydrolyze a broad spectrum of
substrates, including ATP, ADP, and AMP [42]. S. mansoni
alkaline phosphatase (SmAP) has structural homology to human
placental alkaline phosphatase, which suggests that its substrate
specificity is similar to human alkaline phosphatases. In addition,
investigation of the S. mansoni tegument revealed phosphodiester-
ase (SmPDE) activity, which hydrolyzes, among others, ATP and
AMP [43]. Furthermore, a tegument-localized S. mansoni ATP-
diphosphohydrolase-1 (SmATPDase1) activity was characterized,
which is capable of hydrolysis of both ATP and ADP to AMP
[44,45]. Therefore, these tegumental enzymes could, by mimick-
ing human ATPDases, form a potential strategy to inhibit platelet
activation.
Furthermore, the actions of an S. mansoni protein with kallikrein-
like activity, sK1, and a protein with homology to mouse plasma
kallikrein, SmSP1, may form a mechanism through which
schistosomes inhibit primary haemostasis [46,47]. Kallikrein is
able to convert HMWK to the small vasoactive peptide
bradykinin, which is a potent vasodilator [20,48]. Bradykinin
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can trigger the release of prostacyclin (PGI2) from endothelial cells
[48]. PGI2 is another potent vasodilator but also inhibits platelet
degranulation. Exposure on the surface or secretion of the
tegumental proteins sK1 and SmSP1 has been suggested, and it
has been shown that sK1 is able to convert HMWK to bradykinin
in vitro, which suggests the production of bradykinin by these
proteins also during schistosome infection in vivo [46,47].
Kallikrein-like activity has not been described for SmSP1, but its
homology to mouse kallikrein suggests kallikrein-like activity. sK1,
and potentially SmSP1, could thus play a role in the inhibition of
primary haemostasis by the parasite, although such a role has not
been demonstrated.
Interference with Secondary Haemostasis by
Schistosomes
Secondary haemostasis consists of two pathways: the tissue
factor (TF) pathway (extrinsic pathway) and the contact activation
Figure 1. Images of adult schistosomes. Panel A shows a schematic drawing of an adult worm pair. The large adult male embraces the smaller
female worm and both worms have two suckers by which they attach to the blood vessel wall. Panel B shows a scanning electron microscope image
of a single S. mansoni adult male, which is about 1 cm long with a diameter of 1 mm. Panel C shows a cross-section of an adult S. mansoni worm pair
(m, male; f, female; arrows mark the vessel wall) in a mesenteric venule of a mouse. This cross-section illustrates how close the worm pair is to the
vessel wall and suggests the extent to which the worms must disturb blood flow (Panel C is adapted from D. G. Colley and W. E. Secor, PLoS
Neglected Tropical Diseases 2007 [10]).
doi:10.1371/journal.ppat.1003781.g001
Figure 2. Proposed modulation of primary haemostasis by schistosomes. Primary haemostasis consists of the activation of blood platelets
and the formation of a platelet plug. Exposure of subendothelial collagen, due to endothelial damage or the presence of soluble activators or
surfaces of pathogens, can facilitate binding of VWF. Platelets adhere to VWF through GPIb present on their surface, followed by their activation and
degranulation. Platelets release molecules, such as ADP, thromboxane A2, serotonin, and platelet factor 3, which stimulate further platelet
aggregation and activation, stimulate vasoconstriction, and activate secondary haemostasis. Primary haemostasis is inhibited by PGI2 from
endothelial cells, which inhibits degranulation of platelets, and by the degradation of extracellular ADP to AMP and subsequently to the inhibitor
adenosine by endothelial ATPDases, such as CD39. Schistosomes interfere with the primary haemostasis through the proposed degradation of
extracellular ADP by SmAP, SmATPDase1, and/or SmPDE, and potentially stimulate the release of PGI2 through up-regulation of the production of
bradykinin by sK1 or SmSP1. Stimulation is indicated by green arrows. Red lines indicate inhibition. Schistosome proteins are indicated in the shaded
boxes. Abbreviations: glycoprotein Ib (GPIb), High-molecular-weight kininogen (HMWK), prostacyclin (PGI2), Schistosoma mansoni alkaline
phosphatase (SmAP), Schistosoma mansoni ATP-diphosphohydrolase-1 (SmATPDase1), Schistosoma mansoni phosphodiesterase (SmPDE), von
Willebrand Factor (VWF).
doi:10.1371/journal.ppat.1003781.g002
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(intrinsic) pathway [2,49]. The extrinsic pathway is considered to
be the physiologically most relevant pathway and is induced by the
exposure of TF after endothelial damage, but under pathophys-
iological conditions it can also be activated by TF expressed on
immune cells or endothelial cells [3,50]. The intrinsic pathway is
activated by binding of coagulation factor XII (XII) to collagen or
negatively charged surfaces [51,52]. Local accumulation of XII
leads to its auto-activation and induces a cascade of cleavage
reactions that activate other coagulation factors [53]. Finally, both
the extrinsic and intrinsic pathways lead to the cleavage of
fibrinogen to fibrin by thrombin and the formation of a stable
fibrin clot (Figure 3).
Interference with the Activation of Secondary
Haemostasis by Schistosomes
Schistosomes are potential activators of the extrinsic pathway
due to the induction of turbulence and endothelial damage and/or
alteration of endothelial function induced by the adult parasite
and/or the eggs [8,9,16]. Furthermore, elevated levels of tumor
necrosis factor alpha (TNF-a) are present in schistosomiasis
patients, and high TNF-a levels are known to induce TF
expression on endothelial cells in vitro [50,54]. In addition,
increased TF expression is present in monocytes from hepato-
splenic schistosomiasis patients, compared to monocytes of healthy
donors, suggesting the involvement of monocyte TF expression in
the prothrombotic state observed in schistosomiasis patients [54].
However, to date there is no evidence that schistosomes interfere
with extrinsic coagulation [55].
On the other hand, in vitro experiments show that schistosomes
can inhibit the activation of secondary haemostasis in at least two
steps: the activity of thrombin and the activation and activity of
XII, a factor of the intrinsic pathway, suggesting inhibition of
secondary haemostasis during schistosome infection in vivo [55–
58]. Both the extrinsic and the intrinsic pathway lead to the
activation of thrombin. The inhibition of thrombin activity by
schistosomes could therefore be a potential strategy to prevent the
formation of fibrin clots. The S. mansoni antigen Sm22.6 discovered
by Stein and David is expressed in the cytoplasmic layer of the
schistosome tegument but is also present in the host circulation
[59]. The exact role of Sm22.6 in the parasitic life cycle is
unknown, but the protein interacts with thrombin and inhibits its
Figure 3. Proposed modulation of secondary haemostasis and vascular tone by schistosomes. Secondary haemostasis can be activated
through two different pathways: either by the presence of TF or by contact of coagulation factors with collagen, pathogens, or other negatively
charged surfaces. This triggers a cascade of cleavage reactions, ultimately leading to the cleavage of fibrinogen to fibrin and the formation of a stable
fibrin clot. This process is regulated by antithrombin, TFPI, and protein C. Schistosomes potentially interfere with secondary haemostasis at several
steps in the cascade. Schistosome whole worm homogenate blocks the conversion of XII to XIIa and inhibits the actions of XIIa. The proteolytic
activity of thrombin is inhibited by the schistosome antigen Sm22.6. Furthermore, schistosome heparin-like glycosaminoglycans may enhance the
activity of antithrombin and, possibly, TFPI, and the schistosome serpin SHW 4-2 might mimic human antithrombin. The vascular tone can be
influenced by schistosomes through the production of both vasodilating and vasoconstricting eicosanoids and the presence of sK1 and SmSP1 that
could potentially convert HMWK into the vasodilator bradykinin. The green arrows indicate stimulation. Inhibition is indicated by the red lines. The
shaded boxes indicate schistosome proteins. Abbreviations: activated coagulation factor XII (XIIa), coagulation factor XII (XII), High-molecular-weight
kininogen (HMWK), tissue factor (TF), tissue factor pathway inhibitor (TFPI).
doi:10.1371/journal.ppat.1003781.g003
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protease activity [58]. This suggests that Sm22.6 could prevent the
formation of fibrin clots around the adult parasite [58].
Furthermore, thrombin plays an important role in the amplifica-
tion loop of the coagulation cascade through the activation of XI
by thrombin; blocking this protein could interfere with this positive
feedback mechanism.
Schistosomes have also been observed to interfere with the
intrinsic pathway. Whole worm homogenate of S. mansoni inhibits
both the activation and activity of XIIa [55–57]. The molecules
responsible for this inhibitory activity have not been characterized,
and their localization in the adult worm is, therefore, not known.
Further investigations are required to confirm this suggested
activity. Furthermore, the importance of XII in coagulation in vivo
is still debated [60]. XII deficiency does not result in a bleeding
tendency in vivo, in contrast to a decreased coagulation time
observed in in vitro tests [61]. The reason for this discrepancy
remains unclear, but it led to the assumption that XII is not
required for normal haemostasis, although a role has been
suggested in pathological thrombus formation [60]. It should
therefore be stressed that the role of inhibition of XII in prevention
of coagulation during schistosome infections might be very limited.
Another possibility could be that inhibition of XII by schistosomes
is not involved in interference with haemostasis, but instead
functions in the evasion of immune responses by the parasite. XII
is involved in the activation of the complement cascade, and
inhibition of XII by schistosomes might thus be an example of an
immune-evasion strategy rather than a strategy to prevent blood
coagulation [62].
Interference with Regulatory Mechanisms of
Secondary Haemostasis by Schistosomes
Secondary coagulation is regulated by the actions of three
proteins: antithrombin, tissue factor pathway inhibitor (TFPI), and
protein C. Stimulation or mimicking of host mechanisms for the
regulation of blood coagulation could form a potential strategy
employed by schistosomes to interfere with haemostasis.
The serine protease inhibitor (serpin) antithrombin is the major
inhibitor of coagulation proteases [61]. Antithrombin is constitu-
tively present in blood plasma and binds and inactivates thrombin,
as well as coagulation factors IXa, Xa, and XIa. The efficiency of
thrombin binding increases 2,000- to 10,000-fold when anti-
thrombin associates with its cofactor heparin [61]. Schistosomes
could potentially increase antithrombin activity by expressing
heparin or heparin-like molecules, such as heparan sulfate.
Heparan sulfate is a heparin-like molecule that is present on the
surface of endothelial cells and is responsible for the anticoagulant
properties of the endothelium. Heparin-like glycosaminoglycans,
i.e., heparan sulfate and dermatan sulfate, are present in tegument
fractions of S. mansoni [63]. However, the localization of these
heparin-like molecules on the outer tegumental membrane and the
capacity of these molecules to interfere with the haemostatic
system have not been determined.
Furthermore, Blanton et al. identified a serpin in S. haematobium,
SHW 4-2, with high sequence similarity to antithrombin and glial-
derived nexins, which can both bind and inhibit thrombin [64,65].
Surface localization of SHW 4-2 was shown by immunolocaliza-
tion, suggesting that S. haematobium serpin may mimic the actions of
antithrombin and could play a role in the inhibition of secondary
haemostasis.
TFPI, the natural regulator of TF activity, is present in blood
plasma and platelets, and is synthesized by endothelial cells. Its
mode of action is peculiar; TFPI binds and inhibits coagulation
factor Xa. This TFPI-Xa complex subsequently binds to the
TF-VIIa complex, thereby inhibiting further activity of coagula-
tion factor VIIa. TFPI present in plasma is active, but present in
low concentrations and only able to delay the coagulation cascade.
TFPI can be released by degranulation of activated platelets and/
or from the endothelium by heparin and thereby regulate TF
activity [2,66]. The presence of heparin-like molecules on the
outer surface of adult schistosomes suggests that the parasite may
stimulate the release and local accumulation of TFPI from the
endothelium, although this has not been confirmed.
Stimulation of Fibrinolysis by Schistosomes
Besides interference with primary or secondary haemostasis,
schistosomes may also reduce thrombus formation through
stimulation of fibrinolytic pathways. Fibrinolysis by plasmin
controls the degradation of fibrin clots to fibrin degradation
products (Figure 4). The proteolytic activation of plasminogen to
plasmin is stimulated by plasma kallikrein, but mainly by
urokinase and t-PA, which are slowly released from damaged
endothelium [2,67]. Although several reports show no enhance-
ment of fibrinolysis by S. mansoni [55,56], more recent reports
indicate the presence of activators of plasminogen at the surface of
S. bovis [68–70]. Ramajo-Herna´ndez et al. screened tegument
fractions for proteins binding plasminogen and demonstrated that
tegument fractions enhanced the generation of plasmin by t-PA
[68]. Ten proteins that were able to bind plasminogen were
identified; the most prominent ones were enolase, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), and actin. Surface local-
ization was shown for GAPDH and enolase but not for actin
[69,71]. Enolase is expressed on the surface of male schistosomes
only, and recombinantly expressed enolase has been shown to
bind plasminogen and enhance its conversion to plasmin in the
presence of t-PA [68,69]. Similarly, Yang et al. discovered a
plasminogen-binding enolase in S. japonicum, indicating that
plasminogen-binding by schistosome enolases may be a common
feature of schistosomes [72]. The role of GAPDH and actin in the
conversion of plasminogen is still unclear, but it has been described
that interaction of plasminogen with other molecules induces
conformational changes in plasminogen which could aid in the
conversion of plasminogen to plasmin by t-PA [73]. Further
research by de la Torre-Escudero et al. revealed on the parasitic
surface the presence of a schistosome protein belonging to the
family of annexins [70]. Annexins have many functions, and some
annexins, such as human annexin-A2, are involved in the
regulation of fibrinolysis [74]. Schistosome annexin binds
plasminogen and enhances the t-PA mediated conversion of
plasminogen to plasmin [70]. The schistosome surface annexin
may thus have a role in local activation of fibrinolysis during
schistosome infection, thereby stimulating the degradation of
thrombin clots that could be formed at the parasite’s surface.
Interference with the Vascular Tone by
Schistosomes
Besides a possible activation of blood coagulation by the
parasite, the parasite faces a second problem in the bloodstream.
The eggs deposited by the female are laid in the small veins
surrounding the intestine, and the parasite pair is known to
wander between the large portal vein and these small veins [75].
This migration could, due to the large size of the adult worm pair
compared to the size of the blood vessels, temporarily cause
obstruction of blood flow, and the resulting changes in blood flow
could potentially damage the endothelium and surrounding
tissues. Manipulation of the vascular tone, e.g., by inducing
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vasodilation, could prevent damage caused by obstruction of these
small blood vessels, and such a strategy would therefore be
advantageous for the parasite. Several mechanisms have been
proposed by which schistosomes could modulate vascular tone
(Figure 3) (reviewed in detail by Da’dara and Skelly [20]). For
example, schistosomes are able to produce and secrete eicosanoids.
Eicosanoids have diverse functions; among these is influencing the
vascular tone. S. mansoni produces eicosanoids that stimulate
vasodilation (e.g., the cyclo-oxygenase products prostaglandin D2
and prostaglandin E2), as well as 5-lipoxygenase products that
are able to induce vasoconstriction [e.g., leukotriene C4 and
15-hydroxyeicosatetraenoic acid (15-HETE)] [76]. It has been
shown that schistosome vasoconstrictors are released in smaller
amounts than the vasodilators [76,77]. This suggests that
eicosanoids play a role in the stimulation of vasodilation during
infection. However, this difference in production of vasoconstric-
tion-promoting and vasodilation-promoting eicosanoids could also
merely reflect differences in biological activity, and therefore, the
true impact of schistosome eicosanoids on the vascular tone during
infection remains unclear.
Another potential mechanism to induce vasodilation by
schistosomes is through the actions of the schistosome proteins
Figure 4. Proposed modulation of the fibrinolytic system by schistosomes. The fibrinolytic system inhibits blood coagulation through
degradation of the formed fibrin clot by plasmin. Plasminogen is cleaved to plasmin by plasma kallikrein, but mainly by t-PA and urokinase, which are
inhibited by PAI-1 and PAI-2. Furthermore, plasmin activity is inhibited by TAFI. Schistosomes may stimulate fibrinolysis by the presence of enolase,
GAPDH, and annexin, which bind plasminogen and facilitate its conversion to plasmin by t-PA. Green arrows indicate stimulation. Inhibition is
indicated by the red lines. Schistosome proteins are denoted in the shaded box. Abbreviations: tissue-type plasminogen activator (t-PA), plasminogen
activator inhibitor 1 (PAI-1) and 2 (PAI-2), thrombin-activatable fibrinolysis inhibitor (TAFI), glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
doi:10.1371/journal.ppat.1003781.g004
Table 1. Proposed interference with the haemostatic system and vascular tone by schistosome molecules.
Target Schistosome molecule Effect
Hypocoagulation mechanisms
Primary haemostasis
ADP SmAP [40,41] Hydrolysis of ADP to AMP and adenosine, a competitive
inhibitor of platelet aggregation and degranulation.
SmATPDase1 [44,45] Hydrolysis of ATP and ADP to AMP.
SmPDE [43] Hydrolysis of ATP and AMP.
HMWK sK1 [46] Conversion of HMWK to bradykinin. Bradykinin
stimulates the release of PGI2, an inhibitor of platelet
degranulation, from endothelial cells.
SmSP1 [47] Homology to mouse plasma kallikrein.
Secondary haemostasis
Factor XII Schistosome homogenate [55–57] Inhibition of the conversion of coagulation factor XII to
XIIa and the actions of XIIa.
Thrombin Sm22.6 [58] Inhibitor of thrombin activity.
Antithrombin Heparin-like molecules [63] Potential increase of the activity of antithrombin.
SHW 4-2 [65] Sequence similarity to antithrombin.
Hyperfibrinolytic mechanisms
Plasminogen Enolase [68,69,72] Binding and conversion of plasminogen to plasmin by
t-PA.
GAPDH [68] Binding of plasminogen.
Annexin [70] Binding and conversion of plasminogen to plasmin by
t-PA.
Vascular tone
HMWK sK1 [46] Conversion of HMWK to bradykinin.
SmSP1 [47] Homology to mouse plasma kallikrein.
Vasodilation Eicosanoids [20] Both vasodilating and vasoconstricting effects.
doi:10.1371/journal.ppat.1003781.t001
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sK1 and SmSP1 [46,47]. sK1 is a schistosome protein with
kallikrein-like activity, and SmSP1 has homology to mouse
kallikrein, but kallikrein-like activity has not been described for
SmSP1 [46,47]. As discussed before, S. mansoni sK1 and,
potentially, SmSP1 convert kininogen to the potent vasodilator
bradykinin [46].
Concluding Remarks
According to Virchow’s triad, schistosomes are expected to be
potent activators of blood coagulation. However, the parasite has
evolved several mechanisms to actively inhibit blood coagulation
and manipulate the vascular tone, ensuring long-term survival in
the host’s bloodstream (Table 1). Many experiments showed that
primary and secondary haemostasis can be inhibited by the
parasite through a combination of schistosome-specific mecha-
nisms that inhibit key steps in the coagulation cascade and by
schistosome proteins that exploit host mechanisms for regulation
of haemostasis. Furthermore, schistosome proteins may actively
stimulate fibrinolysis and manipulate vascular tone. The many
strategies used by schistosomes to interfere with the haemostatic
system of their host reflect the complex host–parasite relationship.
Although some major discoveries in manipulation of blood
coagulation by schistosomes have been made, additional studies
are required to further understand these mechanisms and
determine their importance during infection. This would provide
more insight into pathways involved in maintaining the parasitic
life cycle within the host and may reveal new targets for the
development of anti-schistosome drugs or vaccines. Furthermore,
mechanisms described here might also be applicable to other
blood-dwelling pathogens and may reveal broad targets for the
development of drugs to be used against these pathogens. In
addition, schistosome molecules that interfere with the haemo-
static system could form potential new antithrombotic or
thrombolytic drugs for the treatment of haemostatic disorders.
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